Nanobiotix Secures $71 Million Agreement with HealthCare Royalty

Nanobiotix, a biotechnology company, has announced a $71 million royalty monetization agreement with HealthCare Royalty (HCRx). This funding will extend Nanobiotix's cash runway to early 2028, supporting development in head and neck cancer and lung cancer. The agreement provides a non-dilutive financial foundation for the company's nanotherapeutic platforms.

The terms include an upfront $50 million payment, with an additional $21 million anticipated after one year, subject to conditions. HCRx will receive a capped portion of royalties and milestones from sales of JNJ-1900 (NBTXR3), Nanobiotix's oncology product. This support fortifies Nanobiotix's financial stability for long-term growth.

The royalty financing will assist Nanobiotix in reaching critical milestones, enhancing self-sustainability, and fostering innovation in cancer treatment. HealthCare Royalty's investment underscores confidence in Nanobiotix's innovative approach to oncology.